Literature DB >> 149438

[Endo-osseous isotope therapy of malignant skeletal disease (author's transl)].

N Firusian.   

Abstract

The intravenous application of 89-strontium for the relief of pain in 43 patients with breast cancer, bronchogenic cancer, carcinoma of the prostate, hypernephroma and lymphoma with generalized bone metastases is reported. A remarkable clinical improvement was achieved in 33 (76.7%) patients. In four patients a transient analgesic effect was observed. In six cases no response could be achieved. The therapeutic effect usually was long-lasting. At the same time, an increase of alkaline phosphatase was observed, which was interpreted as an indication for the stimulation of osteoblasts and osteoid peripheral zones owing to beta-emission of the radioisotope in the affected areas. There was a significant correlation between the concentration of 85Sr in the bone scan and the therapeutic result of 89Sr-therapy. The indication for such therapy and possible late adverse effects of bone-seeking isotopes are discussed.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 149438     DOI: 10.1007/bf00284021

Source DB:  PubMed          Journal:  Z Krebsforsch Klin Onkol Cancer Res Clin Oncol        ISSN: 0084-5353


  16 in total

1.  LATE SKELETAL CHANGES OF DOGS AFFECTED BY RADIOACTIVE STRONTIUM.

Authors:  N N LITVINOV
Journal:  Fed Proc Transl Suppl       Date:  1963 Sep-Oct

2.  THE USE OF P32 IN THE TREATMENT OF SEVERE PAIN FROM BONE METASTASES OF CARCINOMA OF THE PROSTATE.

Authors:  J G SMART
Journal:  Br J Urol       Date:  1965-04

3.  Experiences with P-32 in treatment of metastatic carcinoma of prostate: a preliminary report.

Authors:  R L PARSONS
Journal:  J Urol       Date:  1961-03       Impact factor: 7.450

4.  The late effects of radioactive strontium on bone; histogenesis of bone tumors produced in rats by high Sr89 dosage.

Authors:  S C SKORYNA; D S KAHN
Journal:  Cancer       Date:  1959 Mar-Apr       Impact factor: 6.860

5.  Radioactive phosphorus (P32) studies in transplanted carcinoma. I. Incorporation of P32 measured by surface activity in Walker carcinoma and normal tissues of albino rats.

Authors:  D B SHAHON
Journal:  Cancer       Date:  1959 Sep-Oct       Impact factor: 6.860

6.  Radioactive isotopes and nuclear radiations in the treatment of cancer.

Authors:  J H LAWRENCE; C A TOBIAS
Journal:  Cancer Res       Date:  1956-03       Impact factor: 12.701

7.  [Kinetics of radiostrontium].

Authors:  N Firusian
Journal:  Nucl Med (Stuttg)       Date:  1974-08-31

8.  The use of radioactive phosphorus to treat bone pain in metastatic carcinoma of the prostate.

Authors:  A Morales; R C Burr; A W Bruce
Journal:  Can Med Assoc J       Date:  1970-08-15       Impact factor: 8.262

9.  Suppression of strontium-90-induced development of bone tumors by infection with Bacillus Calmette-Guérin (BCG).

Authors:  A Nilsson; L Révész; J Stjernswärd
Journal:  Radiat Res       Date:  1965-11       Impact factor: 2.841

10.  Radiation dose and its relation to damage in the rabbit tibia following a single injection and daily feeding of 90 Sr.

Authors:  M OWEN; J VAUGHAN
Journal:  Br J Cancer       Date:  1959-09       Impact factor: 7.640

View more
  1 in total

1.  Strontium-89 (Sr-89) chloride in the treatment of various cancer patients with multiple bone metastases.

Authors:  Sadamoto Zenda; Yoshihiro Nakagami; Masamichi Toshima; Satoko Arahira; Mitsuhiko Kawashima; Yoshihisa Matsumoto; Hiroya Kinoshita; Mitsuo Satake; Tetsuo Akimoto
Journal:  Int J Clin Oncol       Date:  2013-07-24       Impact factor: 3.402

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.